The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Oncology

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors
Oncology

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors

MAR 26, 2021
Smectite promotes probiotic biofilm formation in gut for cancer immunotherapy
Biotics and Supplements

Smectite promotes probiotic biofilm formation in gut for cancer immunotherapy

FEB 15, 2021
Fecal transplant turns cancer immunotherapy non-responders into responders
Editor's Choice

Fecal transplant turns cancer immunotherapy non-responders into responders

FEB 10, 2021
Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132
Clinical & Manufacturing

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132

FEB 3, 2021
Persephone Biosciences Initiates the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response
Oncology

Persephone Biosciences Initiates the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response

NOV 23, 2020
Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program
Finance

Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program

OCT 14, 2020
Micronoma Launches with $3 Million Seed Funding
Finance

Micronoma Launches with $3 Million Seed Funding

AUG 19, 2020
A common gut microbe secretes a carcinogen
Editor's Choice

A common gut microbe secretes a carcinogen

APR 4, 2020
Decoding the microbiome for clinical success – Can we increase cancer immunotherapy response rate by exploring metagenomes?
Editor's Choice

Decoding the microbiome for clinical success – Can we increase cancer immunotherapy response rate by exploring metagenomes?

JAN 23, 2020
Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions
Oncology

Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions

JAN 15, 2020
4D Pharma Announces Opening of a Study Investigating MRx0518 in Combination with Radiotherapy in Patients with Resectable Pancreatic Cancer
Oncology

4D Pharma Announces Opening of a Study Investigating MRx0518 in Combination with Radiotherapy in Patients with Resectable Pancreatic Cancer

JAN 6, 2020